Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04781140 · ClinicalTrials.gov registry record · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
A Phase 4 study of Attention Deficit/Hyperactivity Disorder, sponsored by Supernus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 286
- Enrollment target
- 20
- Study locations
NCT04781140 is a Phase 4 study of Attention Deficit/Hyperactivity Disorder that is actively recruiting participants, run by Supernus Pharmaceuticals. The registered enrollment target is 286 participants, roughly in line with the 278-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target. The trial reports 20 study locations across 6 states.
The verdict
NCT04781140, a Phase 4 study of Attention Deficit/Hyperactivity Disorder, is actively recruiting participants, sponsored by Supernus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 286 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 100mg SPN-812
Study Locations (20)
Florida
- Luna Research Center - Coral Gables
- Sarkis Clinical Trials - Gainesville
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Avantis Clinical Research LLC - Miami
- Hope Research Network, LLC. - Miami
- Medical Research Group of Central Florida - Orange City
- Clinical Neuroscience Solutions, Inc. - Orlando
- APG Research LLC - Orlando
- D&H Tamarac Research Center - Tamarac
- Pediatric Neurology and Epilepsy Specialists - Winter Park
Georgia
- Advanced Discovery Research LLC - Atlanta
- Clinical Integrative Research Center of Atlanta - Atlanta
- CenExcel iResearch, LLC - Decatur
- CenExel iResearch, LLC. - Savannah
California
- Advanced Research Center (ARC), Inc. - Anaheim
- Sun Valley Research Center - Imperial
- Alliance Research - Long Beach
Alabama
- The Center for Clinical Trials, Inc. - Saraland
Arkansas
- Preferred Research Partners, Inc. - Little Rock
Colorado
- IMMUNOe Research Centers - Centennial
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04781140
The ClinicalTrials.gov registry entry for NCT04781140 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 278-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit/Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04781140 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT04781140 about?
NCT04781140 is a clinical study titled "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD". This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
What is the current status of trial NCT04781140?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 286 participants. The study started on 2024-03-19. Estimated completion is 2026-06.
What conditions does trial NCT04781140 study?
This clinical trial studies the following conditions: Attention Deficit/Hyperactivity Disorder.
What interventions are being tested in trial NCT04781140?
The interventions under investigation include: Placebo (DRUG), 100mg SPN-812 (DRUG).
Who is sponsoring clinical trial NCT04781140?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04781140 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit/Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening
RECRUITING · Phase 4
-
Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine
COMPLETED · Phase 4
-
Focus Groups in Ethnically and Racially Diverse Families
RECRUITING
-
Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
RECRUITING · NA
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
A Pilot Study of a Remote ADHD Monitoring Program
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.